Sixteen years follow-up results of a randomized phase II trial of neoadjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) compared with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) in stage III breast cancer: GOCS experience

Published 2013 View Full Article

Authors

Keywords

Breast cancer, FAC, CMF, Neoadjuvant chemotherapy, Prognostic factors, Long-term follow-up

Journal

BREAST CANCER RESEARCH AND TREATMENT

Volume 143, Issue 2, Pages 313-323

Publisher

Springer Nature

Online

2013-12-10

DOI

10.1007/s10549-013-2806-5

References

View 4 related references

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Reprint

Contact the author

Find the ideal target journal for your manuscript

Explore over 38,000 international journals covering a vast array of academic fields.

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now